FDA Pipeline Preview, October 2011 (Janssen Biotech, GlaxoSmithKline, Pfizer, Johnson & Johnson, Bayer AG, ApoPharma, BTG, Chelsea Therapeutics, QLT, Neuraltus Pharmaceuticals, Accentia, 4SC, Tarix Pharmaceuticals)
Recent FDA action (through September 2011) related to golimumab expanded label, meningococcal and Hib combination vaccine, desvenlafaxine, rivaroxaban anticoagulant, deferiprone oral iron chelator, glucarpidase experimental treatment, doxidopa, QLT091001, NP-001, cyclophosphamide, resminostat oral pan HDAC inhibitor, TXA127
Complete response
Recommendations for approval
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
